Chronic myelogenous leukemia (CML) is a myeloproliferative disorder that follows a
characteristic clinical course in which a chronic phase of variable duration precedes an …

Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Chronic myelogenous leukemia (CML), a clonal myeloproliferative disorder, results from the
neoplastic transformation of the primitive hemopoietic stem cell [1]. The hallmark of CML is …

Purpose. Chronic myeloid leukemia (CML), a hematopoietic stem cell cancer representing
15–20% of adult leukemias, is discussed. Epidemiology, staging biology, and monitoring …

Chronic myeloid leukaemia (CML) is a clonal multilineage myeloproliferative disorder, which
originates in a single abnormal haemopoietic stem cell. It involves myeloid, monocytic …

BACKGROUND Before the discovery of imatinib mesylate, a Bcr‐Abl selective tyrosine
kinase inhibitor, three agents, interferon‐alpha (IFN‐α), cytarabine (ara‐C), and …

BACKGROUND Chronic myelogenous leukemia (CML) is characterized by a molecular
aberration, a fusion BCR‐ABL gene encoding for aberrant tyrosine kinase activity, which is …

Chronic myeloid leukemia (CML) is sometimes mentioned as the disease of “firsts”. 1) It is
the first disease where the term “leukemia” was used. 2) It is the first neoplastic disorder …

Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia
chromosome and oncogenic signaling by the resulting Bcr–Abl fusion protein …

Over the last decade, the treatment of chronic myeloid leukemia has progressed
tremendously. The first-generation tyrosine kinase inhibitor imatinib is now flanked by two …